Alnylam Pharmaceuticals Inc (NAS:ALNY)
$ 147.76 -1.59 (-1.06%) Market Cap: 18.69 Bil Enterprise Value: 17.62 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 68/100

Alnylam Pharmaceuticals Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript

Jun 08, 2021 / 02:30PM GMT
Release Date Price: $151.08 (+0.41%)
Salveen Jaswal Richter
Goldman Sachs Group, Inc., Research Division - VP

Good morning, everyone, and thank you for joining us. I'm Salveen Richter, a biotechnology analyst at Goldman Sachs, and we're really pleased to have Alnylam here with us. And with us from Alnylam, we have John Maraganore, CEO of the company.

Questions & Answers

Salveen Jaswal Richter
Goldman Sachs Group, Inc., Research Division - VP

With that, John, to start, can you review your P5x25 vision for 2025? And just comment on how you attain your goal of becoming a top 5 biotech company?

John M. Maraganore
Alnylam Pharmaceuticals, Inc. - CEO & Executive Director

Yes. Well, Salveen, first of all, thanks for having us. Always a pleasure to be at this meeting even when it's virtual. So the P5x25 vision for Alnylam really is part of a decade-long heritage of setting 5-year goals at our company.

We first started with Alnylam 5x15, which we launched in early 2011 and then Alnylam 2020, which we launched in early 2015. And this

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot